力生制药(002393) - 2024 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2024 reached ¥1,336,154,449.87, an increase of 15.88% compared to ¥1,153,032,801.76 in 2023[26]. - Net profit attributable to shareholders decreased by 49.00% to ¥184,528,445.53 from ¥361,827,990.02 in the previous year[26]. - The net cash flow from operating activities dropped by 55.87% to ¥88,263,356.41, down from ¥200,006,024.73 in 2023[26]. - Basic and diluted earnings per share fell by 48.57% to ¥0.72, compared to ¥1.40 in 2023[26]. - Total assets at the end of 2024 were ¥5,785,511,812.28, a slight increase of 0.08% from ¥5,780,604,152.82 in 2023[26]. - The company reported a significant decrease in the weighted average return on equity, which fell to 3.74% from 8.04% in the previous year[26]. - The total profit for 2024 was 216 million yuan, a decrease of 48.61% year-on-year, while the net profit was 185 million yuan, down 49%[48]. - The company's total revenue for the pharmaceutical manufacturing sector reached ¥1,336,154,449.87, representing a year-on-year increase of 15.88%[65]. - The total distributable profit for the company is 1,267,378,547.78 CNY, with the cash dividend amounting to 100% of the total profit distribution[170]. Research and Development - The company is increasing R&D investment in new products, particularly in the cardiovascular and chronic disease sectors, to address the anticipated decline in generic drug prices[7]. - The company is committed to maintaining a strong R&D pipeline aligned with market demands to reduce the risks associated with product development failures[6]. - The company has a robust R&D team and is enhancing its talent development and incentive mechanisms to support innovation[6]. - The company is focused on innovation and has been increasing its R&D investments in new drug formulations and technologies[36]. - The company received 16 approvals for new products in 2024, marking a historical high in its R&D achievements[49]. - The company has maintained a R&D intensity of over 7% in recent years, focusing on high-end generics, innovative drugs, and synthetic biology[49]. - The company's R&D investment increased by 21.56% to ¥127,477,849.03 in 2024, representing 9.54% of total revenue[78]. - The number of R&D personnel rose to 354, a 3.81% increase from 341 in 2023, with a notable 36.11% increase in master's degree holders[76]. Market Expansion and Strategy - The company is focusing on international market expansion to enhance its global presence and competitiveness[5]. - The company is actively participating in international competition to increase its brand recognition and influence in global markets[5]. - The company is pursuing a dual-wheel strategy of "industry operation + capital operation" to drive growth[42]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[139]. - The company has a strategic plan for market expansion and is exploring potential mergers and acquisitions to enhance its market position[115]. - The company plans to launch three new products in the next fiscal year, targeting a market expansion of 30% in the domestic market[139]. Operational Efficiency and Cost Management - The company is implementing cost control measures and optimizing production processes to counteract rising production costs[7]. - The company is focused on enhancing its operational efficiency through technological advancements and process improvements in its manufacturing capabilities[114]. - The company has integrated its raw material and formulation production, enhancing its competitive edge in the market[49]. - The company has established a comprehensive internal control system to effectively mitigate operational risks and enhance management efficiency[180]. Corporate Governance and Compliance - The company strictly adheres to corporate governance regulations, ensuring compliance with laws and maintaining transparency in operations[117]. - The company has established a fair and transparent performance evaluation and incentive mechanism for its directors and senior management[119]. - The company ensures timely and accurate information disclosure, with designated channels for investor communication[121]. - The company has independent financial management, with its own accounting system and tax obligations[125]. - The company has implemented strict management of insider information to protect shareholder interests[123]. - The company has maintained a stable governance structure with no penalties or sanctions from regulatory bodies[131]. Environmental Management - The company has established an environmental management system to ensure compliance with waste discharge standards and regulations[187][188]. - The company has implemented measures to address environmental protection laws and regulations, ensuring compliance with national standards[187][192]. - The company reported a total wastewater discharge of 35.66 tons, with no exceedance of the wastewater discharge standards[197]. - The ammonia nitrogen concentration in wastewater was reported at 0.17 mg/L, with a total discharge of 0.008 tons, also within the regulatory limits[199]. - The total volatile organic compounds (VOCs) emissions were recorded at 6.97 mg/m³, with a total discharge of 0.431 tons, meeting the control standards[199]. Employee Management and Training - The total number of employees at the end of the reporting period is 1,604, with 806 in the parent company and 798 in major subsidiaries[159]. - The company implements a labor contract system and adheres to local regulations for salary standards, providing various social insurances and housing funds[161]. - Training programs include GMP awareness, safety regulations, and professional technical training to enhance employee skills and operational standards[162][163]. - The company has initiated a training program for R&D personnel to enhance their professional skills and innovation capabilities[166]. Shareholder and Financial Management - The company plans to distribute a cash dividend of 3.50 CNY per 10 shares, totaling 89,692,756.65 CNY, which represents 48.61% of the net profit attributable to shareholders for the fiscal year 2024[171]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 740.82 million[150]. - The company has proposed to publicly transfer 24.65% equity of Tianjin Daben Pharmaceutical Co., Ltd.[157]. - The company has adjusted its stock incentive plan, with the first grant of restricted stock set at 2,108,400 shares at a price of 9.11 CNY per share[173].